Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2020

View Archived Issues

Turning flexibility into toxicity

Taking the STING out of nuclear DNA

Taisho details antidepressant potential of V1b receptor antagonist THY-1773

Efflux pump furthers antibiotic resistance, but via unexpected mechanism

Polycomb protein EED inhibitors discovered at Shanghai Blueray Biopharma

XuanZhu Pharma identifies new ketohexokinase inhibitors

New STING receptor agonists identified at HitGen

Medshine Discovery patents c-Met inhibitors

Betta Pharmaceuticals identifies new SHP-2 inhibitors

Alkermes initiates phase II ARTISTRY-3 study of ALKS-4230

First patient dosed in phase I/II study of 4D-125

Trefoil Therapeutics initiates first clinical trial of TTHX-1114

Shionogi describes identification of clinical candidate P2X3 receptor antagonist S-600918

BioMarin receives complete response letter from FDA for valoctocogene roxaparvovec

Novel 3C-like protease inhibitors show efficacy in MERS-CoV-infected mice

Early interim data and regulatory update for phase II TRIDENT-1 study of repotrectinib

Enrollment ongoing in phase I study of ZF-874

Novartis initiates phase II study of LRX-712 in patients with knee osteoarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...